Anavo Therapeutics BV

Netherlands - Leiden, South Holland

• 04/05/2023
• Seed
• $9,406,482

Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades.

We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavo is developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications.

Anavo is backed by blue-chip investors M Ventures, INKEF Capital, Taiho Ventures, and Bioqube Ventures.

Related People

Birgit ZechFounder

Germany - ND

• 20 years working experience in Biotech, 15+ years in Business Development
• In depth knowledge of the pharmaceutical and biotech industry
• Excellent track record in deal making and fundraising
• Strong network to leading Pharma and Biotech companies, significant partnering experience in EP, US and JP
• Over 5 years experience in IP management
• Strong background in chemistry (small molecules, kinase inhibitors, protein modeling) and biology (antibodies, next generation scaffolds)

LinkedIn https://www.linkedin.com/in/birgit-zech-472b1614/